<clinical_study rank="117631">
  
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 05, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229085</url>
  </required_header>
  <id_info>
    <org_study_id>SALMOGLEN20906</org_study_id>
    <nct_id>NCT01229085</nct_id>
  </id_info>
  <brief_title>Efficacy Study of the Combination Mometasone + Salicylic Acid in Patients With Psoriasis</brief_title>
  <acronym>Psoriasis</acronym>
  <official_title>CLINICAL ASSESSMENT OF THE EFFECTIVENESS OF ASSOCIATION MONETASONE FUROATE 0.1% SALICYLIC ACID AND 5% FOR SUBMISSION OF OINTMENT TOPICAL DERMATOLOGICAL USE OF LABORATORY Glenmark Pharmaceuticals Ltd, IN PATIENTS WITH PSORIASIS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of the combination of mometasone furoate 0.1% and Salicylic Acid 5%
      in patients of both sexes who presented clinical symptoms of psoriasis of mild to moderate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III clinical trial, systematic sampling, open-label study that evaluated the efficacy
      of the combination of mometasone furoate 0.1% and 5% salicylic acid in 71 patients with
      lesions of mild to moderate psoriasis treated for up to 45 days or less than this, at the
      discretion of the investigator. The results were statistically analyzed and investigational
      data and their conclusions are referred to in this report.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To assess the safety in use as primary end point and end point as effectively isolated secondary association in patients with plaque psoriasis of mild to moderate.</measure>
    <time_frame>45 days of treatment.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will visit the center at weeks 0, 1, 2, 4 and 6 totaling 45 days. Parameters will be evaluated for erythema, plaque size, scaling, itching, thickness of the lesion as well as recording and analysis of adverse effects from treatments.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mometasone 0,1% + salicylic acid 5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>memotasone + salicylic acid</intervention_name>
    <description>mometasone 0,1% + salicylic acid 5%.</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults of both sexes, regardless of color or social class;

          -  Age 18 or older, with good mental health;

          -  Psoriasis patients with mild to moderate;

          -  Patients who agreed to participate and signed the

          -  Clarified (appendix);

          -  Patients who agreed to return for follow-up visits.

        Exclusion Criteria:

          -  Patients who were making use of biologics, corticosteroids or nonsteroidal
             anti-inflammatory and non-steroid, or who made use of these topical medications until
             15 days before inclusion or 30 days before inclusion when the administration was
             orally;

          -  Patients who were exposed to the sun 15 days before the study began or during the
             course of the same;

          -  Patients who were making use of acetaminophen;

          -  Patients who did not agree to the terms described in the IC informed consent, -
             Patients who also had psoriatic plaques of skin disorders caused by fungi or bacteria
             and they were making use of antibiotic or antifungal;

          -  Lions and other types of skin damage that was not psoriasis;

          -  Pregnant and nursing women;

          -  Patients using oral anticoagulants.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LAL Clinica Pesquisa e Desenvolvimento Ltda.</name>
      <address>
        <city>Valinhos</city>
        <state>SP</state>
        <zip>13270000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <lastchanged_date>October 26, 2010</lastchanged_date>
  <firstreceived_date>February 8, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Alexandre Frederico</name_title>
    <organization>LAL Clinica</organization>
  </responsible_party>
  <keyword>Psoriasis, mometasone, salicylic acid.</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    
    <mesh_term>Mometasone furoate</mesh_term>
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Salicylic Acid</mesh_term>
  </intervention_browse>
  
</clinical_study>